Press release
Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Market will be valued at $6.2 billion in 2023
Download Sample copy of this Report at :http://www.marketresearchreports.biz/sample/sample/1049126
Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012, accounting for 13% of the total number of cancer cases. This figure has been gradually rising with increased smoking and the growing elderly population. Lung cancer is a leading cause of death worldwide, accounting for 1.69 million deaths in 2015. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 a high-risk age range for lung cancer. As the aged population is projected to grow, the prevalence of lung cancer is anticipated to increase, acting as a driver for revenue growth.
The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on different NSCLC subtypes, and the presence of various molecular aberrations.
Complete Report Details @ http://www.marketresearchreports.biz/analysis/1049126
In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta, while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapies such as Tarceva, Iressa, Gilotrif, Conmana, Xalkori, Alecensa and Zykadia.
Opdivo and Keytruda are mAbs, immune checkpoint inhibitors targeted towards programmed cell death (PD) 1, and are recent market entrants. The former gained approval for treating advanced or metastatic squamous NSCLC in Japan in 2015 and in Australia and South Korea in 2016, and the latter gained approval in Japan in 2016 for the firstand second-line treatment of patients with PD-L1-positive unresectable advanced/recurrent NSCLC. Tagrisso and Olita EGFR inhibitors that targeted towards EGFR T790M are also recent market entrants, with the former gaining approval in Japan, Australia and South Korea, and the latter approved in South Korea in 2016 for advanced or metastatic patients with EGFR T790M mutation-positive metastatic NSCLC.
There are currently limited options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations. A therapy that targets mutant KRAS abemaciclib is being developed in the pipeline.
Scope
The NSCLC Asia-Pacific market will be valued at $6.2 billion in 2023, growing from $3 billion in 2016 at a CAGR of 10.8%.
How will immunotherapies such as atezolizumab contribute to growth?
What effect will patent expirations of currently branded therapies have on market value?
The NSCLC pipeline is large and diverse, with an increased presence of mAbs and targeted therapies.
What are the common targets and mechanisms of action of pipeline therapies?
Will the pipeline address unmet needs such as limited treatment options for squamous cell patients?
What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?
Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
How have the late-stage therapies performed in clinical trials?
How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
How could changes in risk factors such as population age, smoking habits and pollution influence the market?
Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion.
How do deal frequency and value compare between target families and molecule types?
What were the terms and conditions of key licensing deals?
Reasons to buy
This report will allow you to -
Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
Predict NSCLC market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and co-development deals.
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact Us
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
Email: sales@marketresearchreports.biz
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Market will be valued at $6.2 billion in 2023 here
News-ID: 582620 • Views: …
More Releases from MarketResearchReports.biz
Hydro-flyers Market: Moving Towards a Brighter Future
A hydro-flyer is an adventure sporting device which uses the propulsion of water jet technology to create continuous flight movement, where the lift and movement are controlled by the flyer. Hydro-flyers sporting devices make use of the flow of water power to drive the flyer to reach soaring heights. The rise in water sporting facilities is one of the major factors that promote the growth and demand for hydro-flyers in…
Outdoor Floodlights: Technology and Market Dynamics
Outdoor floodlights is a reliable, highly efficient, and economical solution for a wide range of outdoor applications. These lights are resistant to temperature fluctuations and they remain stable even in extreme climatic conditions. Unlike the traditional lights, floodlights remain stable and functional even in harsh climatic conditions. This makes them ideal for use in any climate and any outdoor application. Outdoor floodlights save a significant amount of energy and consume…
Snow Helmets Market Future Prospects and Regional Outlook
Riders are riding faster and getting bolder day by day. Hence, safety equipment need to be updated as per the requirement and changing time. Earlier, helmets were primarily used by extreme skiers and racers. They were used only on slopes. However, later, the use of helmets was made compulsory. Earlier, bulky black helmets were used by riders, which are outdated at present. Currently, new stylish helmets that can match with…
Predictions for 2019: Global Sparkling Water Dispensers Industry Is Set to Boom
Sparkling water dispensers are equipment used for dispensing carbonated water. These dispensers mix the still, filtered water with carbon dioxide before dispensing. Sparkling water dispensers are mostly used in households and commercial establishments such as amusement parks, hotels, restaurants, and sports arenas. A sparkling water dispenser has separate outlets for hot water and cold water. The hot water outlet does not require a separate filtration process. However, cold water is…
More Releases for NSCLC
Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical…
NSCLC Market Global Industry Analysis and Forecast Till 2027
Any type of epithelial lung cancer that isn't small cell lung cancer is referred to as NSCLC (SCLC). Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common kinds of NSCLC, although there are several more types that are less common, and all types can occur in atypical histologic variants.
Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=562904
Top Key Players Included in This Report: Merck KGa, Roche, Nlyte, Taxotere,…
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail…
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot:
NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit…
Global Non-Small Cell Lung Cancer (NSCLC) Market- Current and Future Players
"The Report Non-Small Cell Lung Cancer (NSCLC) - Current and Future Players provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
GlobalData has released its pharma report, Non-Small Cell Lung Cancer (NSCLC) - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing NSCLC Market. The report identifies and analyses…
Global cancer immunotherapies Market 2016:Melanoma, Prostate cancer, NSCLC
Cancer Immunotherapies has brought an unprecedented change in the global cancer therapies market. Cancer immunotherapy can be defined as, the treatment that deploys the bodys immune system, by joining and boosting innate powers of the immune system to fight cancer.
Over the past few years, cancer immunotherapies have generated new waves of optimism in the global oncology market, unveiling huge untapped potential for the innovators. After years of jostling over how…
